Eugia Pharma Specialties Ltd

General

Total Cases19

Active Cases--

Patents--

CourtsD. Delaware D. New Jersey

TypeOperating Company

Elite Ratings

--

Ratings

Experience

Grade

Trend

DCT

L4

E

PTAB

L4

E

CAFC

L4

C

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
06/07/24	Ferring Pharma Inc v. Eugia Pharma Specialties Ltd 1:22-CV-00017 ( D. DE )	Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Consent Judgment)(mdb) (Entered: 06/07/2024)
06/07/24	Ferring Pharma Inc v. Eugia Pharma Specialties Ltd 1:22-CV-00017 ( D. DE )	CONSENT JUDGMENT ***Civil Case TERMINATED. Signed by Judge Maryellen Noreika on 6/7/2024. (dlw) (Entered: 06/07/2024)
06/06/24	Ferring Pharma Inc v. Eugia Pharma Specialties Ltd 1:22-CV-00017 ( D. DE )	PROPOSED CONSENT JUDGMENT by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S. (Bourke, Mary) (Entered: 06/06/2024)
05/15/24	Ferring Pharma Inc v. Eugia Pharma Specialties Ltd 1:22-CV-00017 ( D. DE )	Letter to The Honorable Maryellen Noreika from Mary W. Bourke regarding mediation. (Attachments: # 1 Text of Proposed Order)(Bourke, Mary) (Entered: 05/15/2024)
05/15/24	Ferring Pharma Inc v. Eugia Pharma Specialties Ltd 1:22-CV-00017 ( D. DE )	REDACTED VERSION of 138 Unopposed MOTION to Stay this Litigation pending a decision by the Federal Circuit in a related Litigation by AuroMedics Pharma LLC, Aurobindo Pharma Ltd., Eugia Pharma Specialties Ltd.. (Dorsney, Kenneth) (Entered: 05/15/2024)
05/10/24	Ferring Pharma Inc v. Eugia Pharma Specialties Ltd 1:22-CV-00017 ( D. DE )	ORAL ORDER DENYING 138 Motion to Stay - Having reviewed Defendant's unopposed motion to stay this litigation (including trial) pending the decision by the Federal Circuit in Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC, No. 23-1460, IT IS HEREBY ORDERED that the motion is DENIED. There are currently other Defendants involved in the trial scheduled to take place during the week of July 15, 2024. In the absence of any representation that the case against those Defendants would also be stayed, it does not appear that staying this litigation would simplify the issues or be an efficient use of the Court's resources. ORDERED by Judge Maryellen Noreika on 5/10/2024. (dlw) (Entered: 05/10/2024) ORAL ORDER DENYING 138 Motion to Stay - Having reviewed Defendant's unopposed motion to stay this litigation (including trial) pending the decision by the Federal Circuit in Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC, No. 23-1460, IT IS HEREBY ORDERED that the motion is DENIED. There are currently other Defendants involved in the trial scheduled to take place during the week of July 15, 2024. In the absence of any representation that the case against those Defendants would also be stayed, it does not appear that staying this litigation would simplify the issues or be an efficient use of the Court's resources. ORDERED by Judge Maryellen Noreika on 5/10/2024. (dlw) (Entered: 05/10/2024)
05/08/24	Ferring Pharma Inc v. Eugia Pharma Specialties Ltd 1:22-CV-00017 ( D. DE )	[SEALED] Unopposed MOTION to Stay this Litigation pending a decision by the Federal Circuit in a related Litigation - filed by AuroMedics Pharma LLC, Aurobindo Pharma Ltd., Eugia Pharma Specialties Ltd. (Dorsney, Kenneth) Modified on 5/10/2024 (dlw). (Entered: 05/08/2024)
05/06/24	Ferring Pharma Inc v. Eugia Pharma Specialties Ltd 1:22-CV-00017 ( D. DE )	Pro Hac Vice Attorney Kimberlynn R. Seifert for Ferring B.V., Kimberlynn R. Seifert for Ferring International Center S.A., Kimberlynn R. Seifert for Ferring Pharmaceuticals Inc., Kimberlynn R. Seifert for Polypeptide Laboratories A/S added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (vfm) (Entered: 05/06/2024) Pro Hac Vice Attorney Kimberlynn R. Seifert for Ferring B.V., Kimberlynn R. Seifert for Ferring International Center S.A., Kimberlynn R. Seifert for Ferring Pharmaceuticals Inc., Kimberlynn R. Seifert for Polypeptide Laboratories A/S added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (vfm) (Entered: 05/06/2024)
05/03/24	Ferring Pharma Inc v. Eugia Pharma Specialties Ltd 1:22-CV-00017 ( D. DE )	Pro Hac Vice Fee - Credit Card Payment received for Kimberlynn R. Seifert. ( re 136 MOTION for Pro Hac Vice Appearance of Attorney Kimberlynn R. Seifert )( Payment of $ 50, receipt number ADEDC-4399699).(Bourke, Mary) (Entered: 05/03/2024)
05/03/24	Ferring Pharma Inc v. Eugia Pharma Specialties Ltd 1:22-CV-00017 ( D. DE )	MOTION for Pro Hac Vice Appearance of Attorney Kimberlynn R. Seifert - filed by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S. (Bourke, Mary) (Entered: 05/03/2024)